Table 1

Demographic, clinical, laboratory, and microbiologic data of the 270 adult patients with teicoplanin-treated MRSA BSIs
Parameter No. (%)
Age (years) (mean ± SD) 71.3 ± 16.3
Gender (male/female) 197 (73.0%)/73 (27.0%)
Charlson comorbidity index (mean ± SD) 4.2 ± 2.3
Primary focus of bacteremia
 Urinary tract 12 (3.8%)
 Respiratory tract 99 (31.0%)
 Surgical wound 21 (6.6%)
 Skin 35 (11.0%)
 Intra-abdominal 7 (2.2%)
 Intravenous catheter 94 (29.5%)
 No obvious focus 51 (16.0%)
Location of onset
 ICU 110 (40.7%)
 General ward 157 (58.1%)
 Community 3 (1.1%)
Deep-seated abscess or osteomyelitis 65 (24.1%)
Infective endocarditis 32 (11.9%)
Septic shock at onset
 Yes 37 (13.7%)
 No 233 (86.3%)
Cardiovascular diseases
 Yes 199 (73.7%)
 No 71 (26.3%)
Respiratory diseases
 Yes 68 (25.2%)
 No 202 (74.8%)
Neurologic diseases
 Yes 86 (31.9%)
 No 184 (68.2%)
Gastrointestinal tract diseases
 Yes 105 (38.9%)
 No 165 (61.1%)
Hepatobiliary tract diseases
 Yes 55 (20.4%)
 No 215 (79.6%)
Genitourinary tract diseases
 Yes 109 (40.4%)
 No 161 (59.6%)
Endocrinologic diseases
 Yes 112 (41.5%)
 No 158 (58.5%)
Malignancies
 Yes 98 (36.3%)
 No 172 (63.7%)
Autoimmune diseases
 Yes 20 (7.4%)
 No 250 (92.6%)
Immunosuppression
 Yes 81 (30.0%)
 No 189 (70.0%)
White blood cell count*
 < 4,000/μL 36 (13.4%)
 4,000 – 12,000/μL 106 (39.3%)
 > 12, 000/μL 128 (47.4%)
Anemia*
 Yes 158 (58.7%)
 No 111 (41.3%)
Thrombocytopenia*
 Yes 112 (41.8%)
 No 156 (58.2%)
Hypoalbuminemia*
 Yes 25 (17.7%)
 No 116 (82.3%)
Abnormal liver function test with clinical significance*
 Yes 24 (12.8%)
 No 163 (87.2%)
CRP (mean ± SD)* 13.2 ± 32.3 (mg/dL)
Impaired renal function*
 Yes 109 (40.4%)
 No 161 (59.6%)
Effective treatment within 48 hours*
 Yes 164 (64.5%)
 No 72 (35.5%)
Clinical response at the end of teicoplanin therapy
 Favorable outcome 171 (63.3%)
 Un-favorable outcome 99 (36.7%)
Day 14 all-cause death 35 (13.0%)
Day 30 all-cause death 71 (26.3%)
MIC of teicoplanin by dilution method*
 ≤1 mg/L 161 (76.7%)
 2 mg/L 46 (21.9%)
 4 mg/L 3 (1.4%)
MIC of teicoplanin by Etest*
 ≤1 mg/L 87 (41.4%)
 1.5 mg/L 86 (41.0%)
 2 mg/L 32 (15.2%)
 > 2 mg/L 4 (1.9%)

*Missing data were noted in white blood cell count (1 patient), anemia (1), thrombocytopenia (2), hypoalbuminemia (83), abnormal liver function with clinical significance (42), abnormal renal function (6), and effective treatment within 48 hours (34). Sequence typing and MIC determination were done in only 210 MRSA isolates.

Wang et al.

Wang et al. BMC Infectious Diseases 2013 13:182   doi:10.1186/1471-2334-13-182

Open Data